Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Director Mark Klein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 28
Captor Capital Corp. announced that it expects to receive $0.45 million in funding Captor Capital Corp announced the issuance of 6.5% unsecured convertible loan notes in the aggregate amount of USD 450,000 to a European based institutional investor on May 27, 2025. The maturity date is May 27, 2026. The Notes are transferable only with Captor’s written consent and in minimum denominations of US$1,000, ensuring structured and secure transactions. Reported Earnings • Sep 01
First quarter 2025 earnings released: EPS: CA$8.72 (vs CA$0.13 loss in 1Q 2024) First quarter 2025 results: EPS: CA$8.72 (up from CA$0.13 loss in 1Q 2024). Revenue: CA$30.9m (up 235% from 1Q 2024). Net income: CA$30.3m (up CA$30.7m from 1Q 2024). Profit margin: 98% (up from net loss in 1Q 2024). Duyuru • Aug 22
Captor Capital Corp., Annual General Meeting, Oct 30, 2024 Captor Capital Corp., Annual General Meeting, Oct 30, 2024. Reported Earnings • Jul 30
Full year 2024 earnings released: CA$3.28 loss per share (vs CA$3.74 loss in FY 2023) Full year 2024 results: CA$3.28 loss per share (improved from CA$3.74 loss in FY 2023). Revenue: CA$36.8m (down 12% from FY 2023). Net loss: CA$11.4m (loss narrowed 12% from FY 2023). Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Interim Chairman Brady Cobb was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • May 17
Now 99% undervalued after recent price drop Over the last 90 days, the stock has fallen 97% to €0.0005. The fair value is estimated to be €0.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has declined by 14%. Reported Earnings • Mar 03
Third quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.016 loss in 3Q 2023) Third quarter 2024 results: CA$0.01 loss per share (improved from CA$0.016 loss in 3Q 2023). Revenue: CA$9.36m (down 14% from 3Q 2023). Net loss: CA$709.5k (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. Reported Earnings • Dec 01
Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.041 profit in 2Q 2023) Second quarter 2024 results: CA$0.01 loss per share (down from CA$0.041 profit in 2Q 2023). Revenue: CA$8.95m (down 17% from 2Q 2023). Net loss: CA$730.7k (down 135% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Duyuru • Aug 05
Captor Capital Corp., Annual General Meeting, Oct 12, 2023 Captor Capital Corp., Annual General Meeting, Oct 12, 2023. Duyuru • Jul 28
Rimstock Holdings Limited cancelled the acquisition of Captor Capital Corp. (CNSX:CPTR) in a reverse merger transaction. Rimstock Holdings Limited entered into a binding letter of intent to acquire Captor Capital Corp. (CNSX:CPTR) for $31.7 million in a reverse merger transaction on July 15, 2022. As per the terms of the transaction, Rimstock’s issued and outstanding share capital in exchange for the aggregate purchase price of $31.7 million, which shall be paid in the following amounts: $22.2 million in shares of Captor Capital, $7 million in cash, which shall be reserved in the treasury of Captor Capital for use by the Resulting Issuer as working capital and $2.5 million in cash as a non-refundable deposit, which will be converted into shares of Rimstock at a fully-diluted valuation of $49.5 million upon the earlier of: (i) the Closing; or (ii) the expiration of the exclusivity period set out under the LOI, which is 180 days from the date of the LOI. Post deal completion, shareholders holding 64.11% stake in Rimstock shall hold 72% stake in the issued and outstanding shares of the Resulting Issuer and current shareholders of Captor Capital shall hold 28% stake in the issued and outstanding Resulting Issuer Shares. It is anticipated that the Resulting Issuer will continue the business of Rimstock under a name to be determined by Captor Capital and Rimstock, which will result in a change of business of the Resulting Issuer and shall be listed on the Canadian Securities Exchange. Upon Closing, the board of directors and executive management of Captor Capital will be reconstituted and consist of a select number of nominees from Rimstock. The completion of the Transaction is subject to a number of terms and conditions, including and without limitation: the negotiation and execution of the Definitive Agreement, completion of mutually satisfactory due diligence, the parties obtaining all necessary third-party consents and approvals, regulatory and shareholder approvals, as required, including the approval of the Canadian Securities Exchange (“CSE”) and other standard conditions of closing for a transaction similar in nature of the transaction.
Rimstock Holdings Limited cancelled the acquisition of Captor Capital Corp. (CNSX:CPTR) in a reverse merger transaction on July 26, 2023. Following the termination of the RTO, the Captor Capital will seek to lift the trading halt on its common shares on the Canadian Securities Exchange. The resumption of trading of the common shares of the Company is subject to the approval of the CSE. Duyuru • Jan 06
An unknown buyer acquired a 8% stake in Captor Capital Corp. (CNSX:CPTR) from SOL Global Investments Corp. (CNSX:SOL) for CAD 1.7 million. An unknown buyer acquired a 8% stake in Captor Capital Corp. (CNSX:CPTR) from SOL Global Investments Corp. (CNSX:SOL) for CAD 1.7 million on January 3, 2022. As a part of transaction, SOL transferred and divested an aggregate of 4,182,316 common shares of Captor and received investment securities with an aggregate deemed value of CAD 1.7 million in consideration. As a result, SOL's holding percentage of Captor Shares was reduced from 17.9% to 9.9% on a non-diluted bases, representing a decrease of 8.0%.
An unknown buyer completed the acquisition of a 8% stake in Captor Capital Corp. (CNSX:CPTR) from SOL Global Investments Corp. (CNSX:SOL) on January 3, 2022. Reported Earnings • Jul 31
Full year 2022 earnings released: CA$0.28 loss per share (vs CA$0.15 loss in FY 2021) Full year 2022 results: CA$0.28 loss per share (down from CA$0.15 loss in FY 2021). Revenue: CA$32.7m (up 102% from FY 2021). Net loss: CA$14.5m (loss widened 143% from FY 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 03
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: CA$0.05 loss per share (down from CA$0.021 loss in 3Q 2021). Revenue: CA$8.40m (up 100% from 3Q 2021). Net loss: CA$2.78m (loss widened 237% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 30
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: CA$0.04 loss per share (up from CA$0.11 loss in 2Q 2021). Revenue: CA$8.47m (up 117% from 2Q 2021). Net loss: CA$2.37m (loss narrowed 45% from 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Sep 01
First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.069 profit in 1Q 2021) The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: CA$6.77m (up 80% from 1Q 2021). Net loss: CA$1.51m (down 157% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 02
Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.28 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$4.20m (up 99% from 3Q 2020). Net loss: CA$824.9k (loss narrowed 92% from 3Q 2020). Is New 90 Day High Low • Jan 28
New 90-day high: €0.40 The company is up 410% from its price of €0.079 on 30 October 2020. The German market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. Is New 90 Day High Low • Jan 12
New 90-day high: €0.22 The company is up 156% from its price of €0.086 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 31
New 90-day high: €0.22 The company is up 230% from its price of €0.066 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Dec 03
Second quarter 2021 earnings released: CA$0.11 loss per share The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: CA$3.91m (flat on 2Q 2020). Net loss: CA$4.33m (loss narrowed 69% from 2Q 2020). Reported Earnings • Dec 02
Second quarter 2021 earnings released: CA$0.11 loss per share The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: CA$3.91m (flat on 2Q 2020). Net loss: CA$4.33m (loss narrowed 69% from 2Q 2020). Reported Earnings • Oct 15
First quarter earnings released Over the last 12 months the company has reported total losses of CA$23.0m, with losses narrowing by 53% from the prior year. Total revenue was CA$13.4m over the last 12 months, up 53% from the prior year. 
